Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients

Fig. 5

Efficacy variables in patients following dose reduction from certolizumab pegol (CZP) 400 mg every 2 weeks (Q2W) to CZP 200 mg Q2W (n = 369). a Mean disease activity score in 8 joints (erythrocyte sedimentation rate) (DAS28(ESR)). bAmerican College of Rheumatology (ACR)20 response rates. c ACR50 and ACR70 response rates. This analysis is presented as weeks following dose-reduction visit (Week 0 is defined as the final efficacy assessment visit where a patient received the CZP 400 mg dose). The sharp decline in patient numbers from week 150 following dose reduction is due to the per-protocol site closures in countries where CZP became commercially available. MMRM mixed model repeated measures, NRI non-responder imputation

Back to article page